PhaseBio is leveraging our ELP biopolymer technology to evaluate additional preclinical and discovery-stage candidates focused in two areas:

  • Proteins and peptides for orphan diseases with high unmet medical needs that may benefit from our technology platform and half-life extension
  • Scientifically or clinically validated proteins and peptides for which our technology platform could enable improved or fast-follower treatments

PhaseBio will disclose specific product candidates when they advance into IND-enabling studies.